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Chapter 1
Evaluating the effectiveness of the Dutch  
screening programme

e v a l u a t i n g  t h e  e f f e c t i v e n e s s  o f  t h e  d u t c h  s c r e e n i n g  p r o g r a m m e  11
In 1989, the national breast cancer service screening programme was implemented in the 
Netherlands. From then, women aged 50-69 (and from 1998 aged 50-75) have been invited to 
the screening programme every two years. In 2007, more than 1.1 million women received an 
invitation to participate in the screening programme.1 The objective of this programme was 
to reduce breast cancer mortality without adversely affecting the health status of those who 
participate.2
The Dutch breast cancer service screening programme has now been running for 20 
years. The current breast cancer mortality reduction can differ from results generated 
from the pilot programmes and randomised controlled trials on which the programme 
was implemented.3-6 There have been many changes over time that may explain these 
differences. Skills and abilities can be different in the wider base of professionals 
carrying out service screening compared to the small group of researchers performing 
the mammography screening in the 1970s and 1980s. Furthermore, the anticipated breast 
cancer mortality reduction might be influenced by changes in baseline risk of breast cancer 
and differences in compliance to the programme. Improvements in mammographic and 
other techniques involved in screening, improvements in therapy and earlier diagnosis 
through increased breast cancer awareness, can also influence the reduction in breast 
cancer mortality.7 
To guarantee a successful programme, all elements of the service screening 
programme itself, further diagnostic procedures and treatment of women for whom the 
screening examination yields abnormal results, have to be of high quality.2 To ensure 
quality, monitoring and evaluation of the performance and impact indicators have to be 
embedded in the ongoing programme. After the start of the Dutch programme in 1989, 
quality assurance has been based on early indicators like the breast cancer detection rate 
and the proportion of screen-detected small invasive cancers (≤10mm).2 In the randomised 
controlled trials of screening a decrease in the incidence of advanced breast cancer was 
approximately proportional to the decrease in breast cancer mortality and could thus 
act as an indicator of the effectiveness of a screening programme. However, this was 
not supported by trends in advanced breast cancer incidence in areas with widespread 
mammographic service screening, showing that advanced disease rate does not replace 
disease-specific mortality as the main end point.8,9 Only 10 to 15 years following the start 
of screening, can reliable outcomes on breast cancer mortality be estimated.10,11 
Breast cancer mortality can be evaluated using different methods: trend analysis, 
modelling, cohort and case-referent study designs.12-16 All methods add relevant and 
valuable information to the evaluation of screening programmes. But only case-referent 
and cohort studies can be used for estimating the net benefit in risk reduction of women 
participating in the screening programme, as they link individual screening data with 
breast cancer death. Of these two methods, case-referent studies are recommended, 
because they are equally valid, more efficient and more cost-effective.17,18 
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However, the case-referent design is only an appropriate and valid method if specific 
methodological complexities are allowed for. The population from which the cases and 
referents are selected are women who received at least one invitation to the screening 
programme. Cases are defined as women who died from breast cancer. Referents are 
selected from the same population and have to be alive at time of death of the case.19-22 
The screening history is collected for all cases and referents. Screening participation of 
the cases is compared with that of the referents. If screening is effective, the participation 
of cases should be lower than the participation of referents. This results in an odds ratio 
below 1, for example 0.80, which indicates a 20% breast cancer mortality reduction 
due to screening. The protective element in screening is the treatment that follows the 
screening test, when the test is truly positive. Therefore, the odds ratio in a case-referent 
study measures the combination of early detection followed by appropriate treatment.23 
A much discussed issue of the case-referent design is how to address the potential 
presence of self-selection bias. Women who accept the invitation to screening may have 
different baseline risks of breast cancer death compared to women who do not accept 
the invitation.19,24 This potential difference in baseline risk can influence the estimate of 
breast cancer mortality reduction due to screening. For instance, if women who accept 
the invitation to screening have a lower breast cancer death risk, the reduction will be 
overestimated. Therefore, the odds ratio estimated from the case-referent study must be 
corrected for self-selection bias if present. 
In 2006, the Dutch Cancer Society (KWF Kankerbestrijding25) approved the project: 
‘Impact of breast cancer service screening in the Netherlands: can case-referent studies 
reliably monitor and evaluate the effect on mortality?’. To address this research question, 
we have estimated the impact of screening mammography at both regional and 
national level, using individual data to directly link screening history with breast cancer 
death (Chapters 3 and 4). In addition, we provide a correction factor for self-selection 
bias, calculated using the incidence-based mortality method based on data from the 
implementation phase of the Dutch screening programme (Chapter 5).26 Recent case-
referent studies in other countries have shown a wide range of breast cancer mortality 
reductions, from 25 to 50%. We have reviewed whether differences in the designs used 
may explain the differing mortality reductions (Chapter 6). In the final chapter, the results 
and the future use of the case-referent design as a monitoring tool for the evaluation of 
the breast cancer screening programme in the Netherlands is discussed (Chapter 7). As 
the impact of screening on mortality is dependent on the incidence in the population, we 
will start off this thesis by looking at trends in baseline morbidity and mortality of breast 
cancer over time (Chapter 2).
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Large increase in a Dutch woman’s lifetime risk of developing breast cancer.
E. Paap, M.J.M. Broeders, G. van Schoor, J.D.M. Otten, A.L.M. Verbeek.
Chapter 2
Lifetime risk of breast cancer in the screening era
18 c h a p t e r  2
Abstract
A large increase in the incidence of breast cancer has been observed in many countries over 
the last two decades. On the other hand, however, breast cancer mortality has decreased. The 
prominent burden of breast cancer in the female population induces a lot of discussion about 
incidence and mortality rates, whereas lifetime risks are less mentioned. This study provides 
information on the changes in risks for Dutch women with regards to being diagnosed with 
breast cancer (both invasive and in situ) or dying from this disease during the screening era.
 We used the life table method to calculate lifetime risks for the period 1989–2003. The 
lifetime risk for developing breast cancer increased from 1 in 10 in 1989 to 1 in 7 in 2003; the 
risk of dying from breast cancer decreased respectively from 1 in 22 to 1 in 26. The increasing 
incidence is alarming but has to be seen in perspective; the decreasing mortality is promising 
and shows that, at most, one third of the breast cancer cases are fatal.
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Introduction
The prominent burden of breast cancer in the female population has resulted in a great 
deal of interest in all topics concerned with breast cancer. Since the implementation of 
service screening in many countries, the changes in both the incidence of and mortality 
rates from breast cancer have been widely discussed in the literature.1,2
The increased incidence and decreased mortality in many European countries is 
demonstrated in a recent study by Héry and colleagues which reported on changes in 
breast cancer incidence and mortality in middle-aged and elderly women in 28 countries.3 
In the Netherlands nearly 13,000 women are diagnosed with an invasive or in situ breast 
carcinoma each year.4
Although rates have regularly been reported in the literature, in the popular press, 
lifetime risk is a widely cited statistic used for communicating risks to the general 
population.5 The lifetime risk represents the average risk at birth that a woman will 
develop breast cancer or die from breast cancer during her lifetime.6 We wanted to know 
the effect of the changes in rates on the individual lifetime risk. This study provides 
information on these changes in lifetime risk over the past two decades.
Patients and methods
Data
To calculate the lifetime risk we have used the life table method. Female breast cancer 
incidence, mortality and population data were obtained from the Netherlands Cancer 
Registry (NCR) and Statistics Netherlands for the years 1989–2003.4,7 We used the absolute 
numbers of newly diagnosed breast cancer patients (invasive and carcinoma in situ) and 
the absolute numbers of breast cancer deaths of age groups of five years: 0–4, 5–9, . . ., 
90–94 and 95+. The 95+ age group included women aged 95 and older. 
Life table method
In 1956, Goldberg and colleagues pioneered the life table method, which calculates the 
lifetime risks by means of a fictitious cohort of women from birth on the basis of life 
expectancy and the current incidence or mortality.8 This estimate of the lifetime risk can 
be computed if data on breast cancer morbidity, mortality and life expectancy tables 
are available.9 For determining the life table risk for breast cancer we used the method 
of Fay and colleagues with DevCan software, version 6.1.0, from the US National Cancer 
Institute.10-12
We estimated the change in risk of developing or dying from breast cancer for two 
different age spans, namely the lifetime risk and the risk until age 75. 
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figure 2.1  Change in risk of developing breast cancer (invasive and in situ) for the period  
1989 - 2003 for the age groups up to 75 and for lifetime
Results
The results in Figure 2.1 show how the risk of developing breast cancer has changed over 
time. Both the lifetime risk and the risk up to 75 years of age show a considerable increase 
in risk over the last two decades. According to the life table method, 10.5% of all women 
born in 1989 will develop breast cancer, while for women born in 2003 this risk increases 
to 13.6%. The risk of developing breast cancer before the age of 75 increases from 7.8% in 
1989 to 10.4% in 2003.
In Table 2.1, we converted the percentages to an individual risk. Using data from 1989, 
1 in 10 women will develop breast cancer. By 2003, this has increased to 1 in 7 women. The 
risk of developing breast cancer before the age of 75 is 1 in 10 in 2003. 
Figure 2.2 and Table 2.1 illustrate the change in risk of breast cancer death during the 
screening era. The lifetime risk of dying from breast cancer declined from 4.6% (1 in 22) 
in 1989 to 3.9% (1 in 26) in 2003. Up to the age of 75, the risk decreased from 2.6% in 1989 
to 2.2% in 2003.
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table 2.1  Individual risks of developing breast cancer and dying from breast cancer for a 
woman born in 1989 and for a woman born in 2003
Risk of developing  
breast cancer
Risk of dying from  
breast cancer
1989 2003 1989 2003
Lifetime risk 10.5%   
1 in 10
13.6%
1 in 7
4.6%  
1 in 22
3.9%
1 in 26
Risk before the age of 75 7.8% 10.4% 2.6% 2.2%
1 in 13 1 in 10 1 in 38 1 in 45
 
figure 2.2  Risks of dying from breast cancer for the age groups up to 75 and for lifetime 
during the screening era
1989
5.0
4.5
4.0
3.5
3.0
2.5
2.0
1.5
1.0
0.5
0.0
1991 1993 1995
year
lt lifetime
lt 75
ri
sk
 %
1997 1999 2001 2003
22 c h a p t e r  2
Discussion
The results of our study show a large increase in the female lifetime risk of developing 
breast cancer over the last two decades. Although this increase is obvious, the reasons 
for it are still debated. One factor that can be associated with the increase is that women 
live longer and die less often from other causes.5 A second possible explanation is the 
change of exposure to risk factors over the past decades – for example, change in risk 
factors related to pregnancy, obesity and mammographic density.13,14 Soerjomataram and 
colleagues observed a strong correlation between the overall excess incidence of breast 
cancer and the average age of the mother at first birth.15 Besides a high average of mean 
age at first birth, populations in countries with a high breast cancer risk tend to have a 
clustering of other risk factors, for example, younger age at menarche and a higher body 
mass index.16 Furthermore, the increase in lifetime risk is often mentioned as an effect 
of the introduction of service screening, which started in the Netherlands in 1989.17 For 
example, overdiagnosis due to service screening has been noted as a possible reason.18,19 
It is, however, unlikely that the increase in incidence is entirely attributed to screening.15 
Even if this debate about the reasons for the increased incidence is solved, the question 
to what extent breast cancer could be prevented will remain. 
In Europe, breast cancer incidence shows an increasing trend in many countries.3,17 
Ferlay and colleagues have demonstrated that, in 2006, the Netherlands, after Belgium 
and Ireland, had the highest incidence rate in Europe.2 This high incidence rate reflects a 
high lifetime risk for breast cancer compared to other European countries. 
Some remarks on the level of the current lifetime risk have to be made. The risk 
estimate is based on the entire female population and is therefore an average. Individual 
lifetime risks depend on the presence or absence of risk factors in the individual woman. 
In addition, surviving to an increased age results in a lower lifetime risk in the remainder 
of a woman’s life.5,20,21 According to the Dutch Cancer Society the current lifetime risk of 
developing an invasive breast cancer for a Dutch woman is 1 in 8. The remaining lifetime 
risk for a woman aged 50 is 1 in 9 and for a woman aged 60, 1 in 12.22 The risk of developing 
breast cancer before the age of 75 (1 in 10) is considerably lower than the lifetime risk, 
because breast cancer incidence increases with age.
Besides an increased chance of developing breast cancer, the results demonstrate a 
decrease in risk of dying from breast cancer. The risk of dying before the age of 75 is 
even lower. The low mortality risk compared to the high incidence risk can be credited to 
diagnosis of breast cancer in an early stage and to improved therapy.1
The implementation of the breast cancer service screening in the Netherlands has 
introduced, among other things, an increase of carcinoma in situ over the last two 
decades.23 In calculating lifetime risks of developing breast cancer, we included patients 
with a carcinoma in situ because these women are treated in the same way as women 
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with a small invasive carcinoma.23,24 It should be pointed out that in using the numbers 
from the Netherlands Cancer Registry, women who develop a second breast cancer 
with a different morphology are counted twice. Inclusion of the carcinoma in situ in 
our calculations will overestimate the risk of developing breast cancer because some 
of these women develop an invasive carcinoma later in life. A rough estimate of this 
overestimation is that the risk of developing breast cancer decreases by 0.2%, which 
would lead to an individual life table risk of 1 in 7.5.
 In conclusion, the breast cancer incidence has increased to a high level and currently 
1 in 7 Dutch women will develop breast cancer sometime during their life. Although the 
incidence has increased, the mortality has decreased during the last two decades and at 
the moment the risk of dying is 1 in 26.
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A remarkable reduction of breast cancer deaths in screened versus unscreened women: 
a case-referent study.
E. Paap, R. Holland, G.J. den Heeten, G. van Schoor, A.A.M. Botterweck,
 A.L.M. Verbeek, M.J.M. Broeders.
Chapter 3
Estimating effectiveness in Mid and South Limburg 
28 c h a p t e r  3
Abstract
Objective  –  We designed a case-referent study to investigate the effect of mammographic 
screening at the individual level, looking at the association of breast cancer death with 
screening history.
Methods  –  The study population included all women aged 50–75 in the province of Limburg, 
the Netherlands who had been invited to the screening program from 1989 to 2006. From this 
population, 118 cases originated who died of breast cancer in 2004 or 2005. The screening 
history of these cases was collected and compared with a sample of the invited population. 
The breast cancer death rate in the screened relative to the unscreened women was estimated 
as the odds ratio (OR). This OR was adjusted for self-selection bias, the difference in baseline 
risk for breast cancer death between screened and unscreened women.
Results  –  Analysis of the data showed a breast cancer mortality reduction of 70% in the 
screened versus the unscreened women (OR = 0.30, 95% CI 0.14–0.63). The magnitude of self-
selection was estimated specifically for Limburg. After correction for self-selection bias, the 
effect of screening increased to 76% (OR = 0.24, 95% CI 0.10–0.58).
Conclusion  –  Screening resulted in a remarkable reduction in breast cancer mortality. 
Contrary to findings in other countries, adjustment for self-selection in Limburg had no 
influence on the impact of screening. Thanks to a well-organized centralized screening 
program, similar results are expected in other regions of the Netherlands.
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Introduction
Several randomized controlled trials conducted in the 1970s and 80s have shown a breast 
cancer mortality reduction of 25–30% in those offered mammographic screening.1 As a 
consequence, many countries initiated a national or regional service screening program. 
In the Netherlands, a population-based program was set up in 1989 with a centralized 
organization, including centralized technical and medical quality control, and audit.2
Since the introduction of service screening in the Netherlands, there has been a large 
decrease in breast cancer mortality. A trend study by Otten et al. provided support for a 
time relation between the implementation of screening and its effect on breast cancer 
mortality.3 This mortality reduction was preceded by a significant decrease in advanced 
disease from 1995 onwards.4 Although trend studies suggest that screening affects breast 
cancer mortality, they cannot show a direct link between screening performance and 
breast cancer death. Other factors like improvements in therapy could also be (partially) 
responsible for the decrease in mortality.5 Therefore, individual data on screening history, 
diagnosis and breast cancer death should be analysed.
In the Dutch screening program, women aged 50–75 are invited for biennial 
mammography screening. During the performance of our study, one of the regions which 
organized breast cancer screening was the Comprehensive Cancer Centre Limburg (IKL). 
The IKL covers a large part of the province of Limburg with a female population of 450 000 
representing 6% of the Dutch female population. 
In this region, no study has yet estimated the relation of breast cancer death with 
screening history at an individual level. An efficient method for evaluating this relation 
is the case-referent study.6 This design requires consideration of self-selection bias since 
women who accept the invitation to screening may have a different baseline risk for 
breast cancer death a priori than women who do not accept the invitation.7
The aim of this study was to evaluate the association between service screening and 
breast cancer mortality in the province of Limburg using a case-referent design. We were 
able to adjust this effect for self-selection based on differences in baseline risks of breast 
cancer death by screening status in the female population of Limburg.
Methods
Study population
The study population included women aged 50–75 who received at least one invitation 
to the service screening program in the IKL-region. During our study, the IKL included 
both a cancer and a screening registry. The cancer registry collects data on all patients 
with breast cancer in the covered region. The screening registry holds individual data 
on invitation and participation for all women in the target population of the service 
screening program in the IKL-region. 
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We applied a case-referent design to evaluate the effect of current mammographic 
screening on breast cancer mortality. Cases originated from the study population 
and were defined as women who died from breast cancer in 2004 or 2005. The cause 
of death as reported in death certificates was obtained through linkage with Statistics 
Netherlands. Data collection for cases included date of death, date of diagnosis, date of 
birth and the complete screening history. For each case, one referent was sampled from 
the study population. The referent was matched for year of birth and area of residence. 
She had to be free of breast cancer at the moment she received the invitation to screening 
(index invitation) and had to be alive at time of death of the case. The complete screening 
history of each referent was also included in the database. The case and her matched 
referent formed a case-referent set. 
Definition of exposure to screening
The screening history of cases and referents included their dates of invitation and the 
dates of their screening tests if they participated. Screening participation can only 
influence breast cancer death if the screening examination is performed in the period 
when the cancer is potentially detectable on the mammogram — in the detectable 
preclinical period (DPCP). Therefore, for each case, we set the opportunity to exposure 
to screening to be the most recent invitation date preceding the diagnosis, the index 
invitation.8 In the case-referent set, the referent was also assigned an index invitation 
from the same screening round from which the index invitation of the case was selected. 
Both the case and the referent are classified as screened if they participated in the 
screening examination following their index invitation. For screen-detected cases, this 
was the screening examination at which the breast cancer was detected.
The exact duration of the DPCP varies for cases, but will probably not exceed four to six 
years, based on estimates of lead time for breast cancer diagnosis.8,9 Including only the 
index invitation to classify exposure to screening could lead to underestimation of the 
effect of screening.9 In an additional analysis, we therefore expanded the opportunity for 
exposure to screening to the invitation preceding the index invitation.
Statistical analysis
The case-referent comparison relates screening participation at the index invitation to 
breast cancer death. The breast cancer death rate in the screened versus the unscreened 
women was assessed and represented as an odds ratio (OR). This was achieved by 
calculating the Mantel–Haenszel odds ratio and its 95% confidence interval by means 
of conditional logistic regression, taking into account, the matching for year of birth 
and area of residence. Matching the referent to the case leads to four possibilities for 
a case-referent set: the case and referent are both screened; the case is screened but 
the referent not; the case is not screened but the referent is; both the case and referent 
are not screened. The OR for a matched case-referent study only includes the discordant 
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case-referent sets. The OR is calculated as the number of sets where the case is screened 
and the referent is not, divided by the number of sets where the case is not screened and 
the referent is.10
Self-selection bias
In the evaluation of breast cancer screening, much attention has been paid to self-
selection bias.11 Participation in screening is based on a voluntary decision. Therefore, 
the baseline risk for breast cancer death could be different beforehand in the screened 
women compared to the unscreened women, for example due to differences in ethnicity, 
history of relatives with breast cancer, or socioeconomic circumstances.12-14 To correct 
for potential self-selection bias, we calculated a correction factor specifically for the 
IKL-region using the incidence-based mortality (IBM) method of Paci et al.15 To this end, 
we used data of women eligible for invitation to screening during the implementation 
period of the screening program (1990–1995). For this period, we calculated the IBM 
rate for women not yet invited to the screening program and for women invited, but 
not screened. The numerator of the IBM rates included breast cancer deaths of women 
diagnosed with breast cancer in the years 1990–1995. In total, 188 uninvited and 34 not 
screened breast cancer deaths were identified. The person years in the denominator were 
calculated with data on the number of invited, number of screened and the total female 
population in the years 1990–1995. The correction factor is the relative risk of breast cancer 
death for not screened versus not yet invited women.16 For the IKL-region, the correction 
factor was 0.84 (95% CI: 0.58–1.21), indicating a lower baseline risk in women who do not 
attend screening. This factor was used in a formula developed by Duffy et al. to correct 
the estimated odds ratio for self-selection bias.16,17
Results
In total, 118 cases and 118 referents were selected in the IKL-region. The mean age at index 
invitation for the cases was 61.7 (range 49.4–75.3). Table 3.1 shows the number of case- 
referent sets according to their participation in screening following the index invitation. 
The breast cancer mortality reduction was 70% in screened women compared to 
unscreened women (OR = 0.30, 95% CI 0.14–0.63). As mentioned in the methods section, 
this odds ratio has to be corrected for self-selection bias. Table 3.2 shows the formula 
of Duffy et al.: ORadjusted = p ψ Dr/(1-(1-p)Dr), where p is the attendance rate for service 
screening in Limburg (82%), ψ the uncorrected odds ratio (0.30) and Dr the correction 
factor for self-selection bias (relative risk of breast cancer death; 0.84). This formula 
results in a mortality reduction of 76% (OR = 0.24, 95% CI 0.10–0.58).16
If we expanded the opportunity for exposure to screening to the invitation preceding 
the index invitation in the analysis, the achieved mortality reduction changed slightly 
from 70 to 73% (OR = 0.27, 95% CI: 0.12–0.62).
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table 3.1  Case-referent sets, their participation in the screening examination following their 
index invitation and the calculated odds ratios
Number of case-referent sets
Case and referent both screened 69
Case screened, referent unscreened 9
Case unscreened, referent screened 30
Case and referent both unscreened 10
Total of case-referent sets 118
Odds Ratio (95% CI) 0.30 (0.14-0.63)
Odds Ratio adjusted for self-selection (95% CI) 0.24 (0.10-0.58)
table 3.2  Effect of screening on breast cancer mortality: odds ratio adjusted for self-
selection bias
Formula of Duffy16 p ψ Dr /(1-(1-p)Dr)
Where
ψ - unadjusted odds ratio (95% CI) 0.30 (0.14-0.63)
p - attendance rate of screening in Limburg 0.82
Dr - correction factor for self-selection in IKL-region (95% CI) 0.84 (0.58-1.21)
0.82 x 0.30 x 0.84 / (1-0.18 x 0.84)
OR adjusted for self-selection bias (95% CI) 0.24 (0.10-0.58)
Discussion
In this study, we report two important findings, namely a remarkable breast cancer 
mortality reduction of 70% in screened women compared to unscreened women, and 
continuation of this effect of screening after adjustment for self-selection bias. In other 
countries, estimates of the impact of service screening on breast cancer mortality showed 
reductions of 34–65%, however, with no adjustment for self-selection bias.18 In view of 
these findings, our results indicate a higher impact of mammographic service screening 
on breast cancer mortality in the IKL-region. 
A number of reasons for this remarkable effect of screening in the Netherlands can 
be put forward. It could result from the high-quality screening in a centrally organized 
program.2 A second reason could be improvements due to progression in quality assurance 
and advancements in mammographic techniques. In addition, improvements in therapy 
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could also have resulted in a larger combined effect of screening and therapy. Breast 
cancer screening can only reduce mortality if early diagnosis is followed by appropriate 
(early) treatment. For example, adjuvant systemic therapy was introduced and used 
on a large scale before the implementation of the screening program, which probably 
contributed considerably to the breast cancer mortality reduction.5 
The influence of self-selection in the province of Limburg was minor. After adjustment 
for self-selection, the mortality reduction in screened women changed from 70 to 76% 
compared to unscreened women. This is contrary to results obtained in other countries, 
where the impact of screening reduced after correction for self-selection (breast cancer 
mortality reductions of 34–65% before and 25–50% after adjustment for self-selection).18 
In our study, we calculated a correction factor for self-selection specifically for the 
province of Limburg, indicating a lower baseline mortality risk in women not attending 
screening. Recent case-control studies used a correction factor for self-selection based 
on data from randomized controlled trials in Sweden and Canada.7,16,17 This correction 
factor was 1.36, indicating a higher baseline mortality risk in the unscreened women. Two 
other case-control studies also calculated their own correction factor, of 1.11 and 1.17.19,20 
These differences show that self-selection can differ in magnitude and direction between 
countries or regions. This demonstrates the importance of using a regional or national 
correction factor for self-selection, where possible. Factors which could be associated 
with lower breast cancer risk factors in unscreened women in Limburg are unclear, but 
could for example be due to a lower number of relatives with a history of breast cancer, to 
differences in socio-economic status, to ethnicity, or to screening outside the screening 
program in unscreened women.13,14,21-24 Further research should explore the background of 
the lower baseline risk for breast cancer death in unscreened women in the IKL-region. 
The primary analysis of the association included participation of the case and referent 
following the index invitation. The additional analysis including the invitation prior to 
the index invitation, resulted in a small change in the mortality reduction from 70 to 
73%. This indicates that the underestimation of the DPCP is of minor impact in our study. 
Because the region of the IKL is small, the number of cases and referents is quite 
low (118 case-referent sets). Despite this low number, the confidence interval has an 
acceptable range: from 0.14 to 0.63. This is also true for the calculation of the correction 
factor for self-selection. At this moment, more regions in the Netherlands are being 
included in a multi-region study to support our findings in the IKL-region. Thanks to the 
well-organized centralized and medically audited screening program, we expect similar 
results in these regions.2 
In conclusion, the service screening in Limburg resulted in a remarkable reduction 
of breast cancer mortality. This study includes a correction factor calculated specifically 
for this region using the incidence-based mortality method. Contrary to other countries, 
adjustment for self-selection had no influence on the impact of screening. Although 
disadvantages of screening exist, for example overdiagnosis25,26, the positive results from 
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our study show a clear breast cancer mortality reduction, the ultimate benefit of breast 
cancer screening.
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Abstract
Background  –  Mammographic screening programmes have been implemented in many 
Western countries to reduce the burden of breast cancer mortality, however the benefits are 
still subject to debate. We investigated the benefit of the Dutch population-based screening 
programme by analysing the reduction in breast cancer mortality using individual invitee 
data. 
Methods  –  In a large multi-region study, we identified all breast cancer deaths in 2004 and 
2005 in women diagnosed with breast cancer in the age group (50-75y) invited for screening. 
Women who died of breast cancer (cases) were individually matched for year of birth and 
area of residence to referents from the population invited to screening. Individual screening 
histories were used to calculate the odds ratio (OR), which represents the breast cancer death 
rate in screened versus unscreened women. The OR was adjusted for self-selection bias using 
regional correction factors for the difference in baseline risk for breast cancer death between 
screened and unscreened women. 
Results  –  A total of 1233 cases and 2090 referents were included in this study. We found a 
58% reduction in breast cancer mortality in screened versus unscreened women (OR = 0.42 , 
95% CI 0.33-0.53).  
Conclusion  –  Our study shows that the Dutch breast cancer screening programme leads to 
a substantial reduction in breast cancer mortality, demonstrating the effectiveness of this 
programme. Communication of these results to the women invited to the screening programme 
could help them make a balanced decision about the value of attending screening. 
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Introduction
Screening mammography is effective in reducing breast cancer mortality for women 
aged 50-69, as demonstrated in breast cancer screening trials in the 1970s and 1980s.1 
On the basis of these trial results, mammographic screening programmes have been 
implemented in many Western countries in the 1990s to reduce the burden of breast 
cancer mortality. Currently, the benefits are still subject to debate. It is questioned 
whether the mortality reduction is large enough to justify the harms of screening.2,3 
A few recent studies that compare invited with not-invited areas within the same 
countries have not found a (large) effect of current mammography screening programmes, 
whilst others did.4-8 This type of analysis potentially underestimates the effect of 
screening in subjects actually screened, due both to noncompliance in the invited areas 
and contamination (‘ad hoc’ screening) in the not-invited areas.9 To communicate the 
level of protection that an individual woman can expect if she complies with screening, 
it is more relevant to compare screened with not screened women.10,11 However, this 
comparison has been criticized because self-selection bias could distort the relation 
between screening mammography and breast cancer mortality. 
To assess the effect of screening on breast cancer mortality reliably, it is necessary 
to directly link a woman’s cause of death and her screening history.12 In this study, we 
estimated the benefit of the current Dutch population-based screening programme by 
comparing breast cancer mortality in screened versus unscreened women. To adjust for 
self-selection bias, we provided regional correction factors for potential self-selection 
bias estimated from the implementation phase of the Dutch programme.13
Patients and methods
 
Dutch breast cancer screening programme
A population-based breast cancer service screening programme was gradually 
implemented in the Netherlands from 1989 onwards. Dutch screening policy recommends 
bilateral mammography for all women aged between 50 and 69, with a biennial screening 
interval. Coverage of the target population, that is, the percentage of eligible women 
annually invited, increased from 11% in 1990, to 69% in 1993, and to full population 
capacity in 1996. In 1997, the upper age limit was extended to 75 years with full coverage 
in 2001. In 2007, more than 1.1 million women received an invitation to participate in the 
screening programme, and over 900,000 women were screened (mean overall attendance 
rate of 82.4%).14
Between 1989 and 2009 the organization of the screening programme was executed 
by nine regional screening organisations. Of these, five have been included in our study: 
Stichting Kankerpreventie en -screening Limburg (SKsL), Stichting Kankerpreventie IKA 
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Source: www.bevolkingsonderzoekborstkanker.nl (screening regions between 1989 and 2009)
figure 4.1  Five out of nine screening regions included in our case-referent study: SKsL, SKP 
IKA, BBNN, SVOKON and SBBZWN
(SKP IKA), Stichting Bevolkingsonderzoek Noord-Nederland (BBNN), Stichting Vroege 
Opsporing Kanker Oost-Nederland (SVOKON) and Stichting Bevolkingsonderzoek 
Borstkanker Zuidwest Nederland (SBBZWN). Those screening regions cover more than 
half of the target population for screening in the Netherlands and were selected based 
on the geographical distribution of rural and urban areas (Figure 4.1) and early and late 
implementation of the screening programme. The screening organisations have screening 
registries which hold individual data on invitation, participation and screening outcome 
for all women in the target population of the service screening programme. 
Study population
Our study population included all women aged 50–75 years who received at least one 
invitation to the service screening programme in the five participating screening 
regions. Cases for the case-referent study originated from the study population and were 
defined as women who died from breast cancer in 2004 or 2005. All members of the 
study population were linked with the Netherlands Cancer Registry to identify breast 
cancer patients who died in 2004 or 2005. The cause of death is not known in the Cancer 
Registry. Therefore, the breast cancer patients who died in 2004 or 2005 were then linked 
with the of Cause of Death Registry of Statistics Netherlands to obtain cause of death as 
reported in death certificates.
SVOKON
PREVEN-
TICON
SVOB
BBNN
IKA
BOBW
SBBZWN
BOBZ
SksL
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Data collection for cases included date of death, date of diagnosis, date of birth and the 
complete screening history. Cases were only included if their date of diagnosis was after 
the date of their first invitation. For each case, referents were sampled from the study 
population. For the first two screening organisations included in this study, SKsL and 
BBNN, one referent was matched to each case, due to financial constraints. In the other 
three organisations it was possible to include two referents for each case. The referents 
were matched for year of birth and area of residence. They had to be free of breast cancer 
at the moment they received the invitation to screening and had to be alive at the time 
of death of the case. The complete screening history of each referent was also included in 
the database. The case and the matched referent(s) formed a case-referent set.
Screening history
Screening participation can only influence breast cancer death if the screening 
examination is performed in the period when the breast cancer is potentially detectable 
on the mammogram before symptoms appear.15 The exact duration of this period is 
unknown for the individual patient, but will most probably be within a 4-year period 
before clinical breast cancer diagnosis, based on estimates of lead time for breast cancer 
diagnosis.15,16 
For this reason, we looked at screening participation for each case with a maximum of 
two screening rounds preceding the diagnosis. The most recent invitation before diagnosis 
is termed the index invitation. In the case-referent set, the referent was also assigned 
an index invitation from the same screening round from which the index invitation of 
the case was selected. Both the case and the referent are classified as screened if they 
participated in the screening examination following their index invitation and/or the 
invitation in the screening round before the index invitation. For screen-detected cases, 
this was the screening examination at which the breast cancer was detected. 
Self-selection bias
Self-selection is present when women who decide to participate in screening have a 
different baseline risk of breast cancer mortality to those who decide not to participate. 
This could be due, for example, to differences in ethnicity, history of relatives with breast 
cancer, or socioeconomic circumstances.17-19 To correct for potential self-selection bias, we 
calculated a correction factor for each region using the incidence-based mortality (IBM) 
method.20 Data was gathered from women eligible for invitation to screening during 
the implementation period of the screening programme (1990–1995). We calculated the 
IBM rate for women not invited to the screening programme and for those invited, but 
not screened. The numerator of the IBM rates included breast cancer deaths of women 
diagnosed with breast cancer in the years 1990–1995: in total, 2631 uninvited and 345 
not screened breast cancer deaths were identified. The person years in the denominator 
were calculated using data on the number of invited, number of screened and the total 
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female population in the same period. The correction factor is the rate ratio of breast 
cancer death for not screened versus not yet invited women.21 Ultimately, the correction 
factor can be used to adjust a difference in baseline risk for not screened versus screened 
women. A detailed description of the estimation of the regional correction factors can be 
found in Paap et al.13 
Statistical analysis
To estimate the effect of screening on breast cancer mortality, we used conditional logistic 
regression to calculate odds ratios (OR) and the 95% confidence interval, taking into 
account the matching for year of birth and area of residence. The OR indicates the breast 
cancer death rate in screened versus unscreened women. Sub-analyses were conducted 
for each of the five regions separately. To adjust for self-selection bias we first adjusted 
the regional ORs with the formula developed by Duffy et al., because heterogeneity 
between the regional correction factors was shown.13,21 After that, we pooled the regional 
corrected ORs to provide a national estimate for breast cancer mortality reduction due to 
screening, using the inverse variance method.22
Results
A total of 1233 cases and 2090 referents were included in this study. Of the cases, 49% were 
aged 49-59 at the index invitation, 38% aged 60-69 and 13% aged 70-75 years. Because 
cases and referents were matched for year of birth, the percentages for the different age 
groups were the same for the referents. The mean age at diagnosis for the cases was 61.9 
(standard deviation 7.3) years. Most cases were diagnosed in the years 2001-2005 (53%) 
compared to 36% in the years 1996-2000 and 11% in the years 1990-1995.
Without correction for self-selection bias, the overall OR showed a breast cancer 
mortality reduction of 52% (OR = 0.48, 95% CI 0.40-0.58) for screened women compared 
to not screened women (Table 4.1). The regional ORs, without correction for self-selection, 
ranged from 33% (OR = 0.67, 95% CI 0.42-1.08) mortality reduction in the BBNN region to 
73% (OR = 0.27, 95% CI 0.12-0.62) in the SKsL region. 
In the SBBZWN, SKsL and SVOKON regions the correction factor was around one, 
indicating no presence of self-selection in those regions. The correction factor for BBNN 
was 0.64 (95% CI: 0.46-0.90) and for SKP IKA 0.77 (95% CI: 0.63–0.93), both indicating a 
lower baseline risk in women who do not attend screening versus screened women (Table 
4.1). An example of the correction for self-selection is given in Table 4.2 for the region of 
BBNN. 
The pooling of the regional adjusted ORs resulted in a breast cancer mortality reduction 
of 58% (OR = 0.42, 95% CI 0.33-0.53, Table 4.1). 
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Discussion
Our results demonstrate a breast cancer mortality reduction of 58% (OR = 0.42, 95% 
CI 0.33-0.53) due to breast cancer screening. The protective element in screening is the 
treatment that follows the screening test, when the test is truly positive. Therefore, the 
odds ratio in a case-referent study measures the combination of early detection followed 
by appropriate treatment.23 A special feature of this study is that we used regional-specific 
correction factors to adjust for self-selection bias, which showed only a minor influence 
on the overall effect estimate in the Netherlands. Only a limited number of studies have 
used country or region-specific estimates for self-selection.7,8,24,25 
In this large multi-region study we have estimated the current benefit of screening. An 
optimal screening effect is not achieved in the first years of screening because prevalent 
screen-detected cases benefit less.26,27 Prevalent screen-detected cases are women 
diagnosed in the first round of screening or in a woman’s first test at a subsequent 
round.20 Therefore, they dominate the first years of the implementation of screening 
programmes. By including cases who died in 2004 or 2005, the proportion of women 
diagnosed in the first years after the start of a screening programme is small and results 
in an estimate of the current benefit of the screening programme. 
In other countries, 25 to 50% breast cancer mortality reductions have been found 
when comparing screened women to unscreened women.28,29 In the Netherlands, regional 
estimates of the impact of screening have consistently demonstrated the effectiveness of 
the Dutch screening programme in those regions.30-32 In line with these regional studies, 
this nationwide study confirms that the centrally organised Dutch population-based 
screening programme is highly effective in reducing breast cancer mortality. 
Our result is at least consistent with the results from the breast cancer screening trials 
from the 1970s and 1980s, after adjusting for contamination and non-compliance.10 The 
randomised controlled trials showed mortality reductions of 20-30% based on intention 
to treat analyses, thus comparing the breast cancer mortality in invited women with not-
invited women. Translation of our effect in those actually screened to an intention to 
treat analysis would result in a reduction equivalent to 48% (95% CI 39%-56%).21 
A major criticism of observational studies is that women who attend screening might 
differ from those who do not, so that any observed effect might not be causal. When 
nationwide screening is offered to all women in the target group, a well-defined control 
group is no longer available. In this situation, the only period from which a control 
group can be created is directly before the start of the implementation of a screening 
programme or during the implementation of the screening programme, when part of the 
target group is still not-invited. 
During the implementation phase of the Dutch screening programme, the female 
population in the targeted age group shifted from an uninvited population to an invited 
population, providing us with contemporaneous groups of not invited and invited but 
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not screened women. Therefore, we adjusted for self-selection using correction factors 
based on breast cancer patients diagnosed in the period 1990 to 1995. Correction for 
self-selection bias of an estimated odds ratio for recent years would assume that the 
differential between the non-screened and not-invited women does not change over 
time. This assumption is inevitable, but is supported by the high and stable attendance 
rate in the Netherlands, which suggests that the non-screened women have not changed 
over time.
Age is strongly related with both the occurrence of breast cancer death and screening 
participation. In this study we matched for age, thereby correcting for the influence of 
this confounder. Other than age there is no background information available on other 
possible risk factors for breast cancer. Other risk factors like mammographic density, 
socioeconomic status and obesity could theoretically distort the relation between breast 
cancer screening and breast cancer mortality, however we demonstrated that these 
factors only play a minor role in the evaluation of screening programmes.33 Therefore, we 
assume that any other confounding factors will not change the estimated benefit of the 
screening programme largely.
In conclusion, the current Dutch breast cancer screening programme has achieved 
a substantial reduction in breast cancer mortality. Because the benefits found in this 
study are based on screened versus unscreened women, communicating these results to 
the invited population could help women make a balanced decision about the value of 
attending screening.
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Minor influence of self-selection bias on the effectiveness of breast cancer screening 
in case-control studies in the Netherlands.
E. Paap, A.L.M. Verbeek, D. Puliti, M.J.M. Broeders, E. Paci.
Chapter 5
Addressing self-selection bias
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Abstract
Background – Self-selection bias is considered to be a problem when evaluating the 
effectiveness of breast cancer service screening in case-control studies.
Objective – Using the incidence-based mortality method (IBM), a correction factor for the 
potential influence of self-selection can be derived from a group of non-screened women and 
a group of not-invited women.
Methods  –  Breast cancer patients, diagnosed in 1990-1995 between the ages of 50 to 70, were 
selected from the Netherlands Cancer Registry and five screening regions in the Netherlands. 
Person-years were calculated for non-screened and not-invited women by using population 
data available on the number of women invited, the number of women screened and the total 
population. Incidence-based breast cancer mortality rates according to screening status were 
calculated for the five screening regions.
Results  –  Between 1990-1995, 15 541 patients were diagnosed with breast cancer. An analysis 
of ten year follow-up after diagnosis resulted in 3903 breast cancer deaths, of which 2631 were 
not-invited and 345 were non-screened. Poisson regression analysis showed heterogeneity 
between the regions with a range of IBM ratios from 0.64 (95% CI 0.46-0.90) to 1.08 (95% CI 
0.82-1.43).
Conclusions  –  Heterogeneity between the regions stresses the importance of a country- and/
or region-specific estimate of self-selection. Adjusting for self-selection bias in the regional 
case-control studies would not change the breast cancer mortality reduction in three regions 
and would result in an even larger effect in two regions. Looking at the range of IBM ratios the 
overall influence of self-selection in the Netherlands is minor. 
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Introduction
The case-control study is regularly used as a tool for the evaluation of the effect of 
screening on breast cancer mortality.1-8 A problem associated with case-control studies is 
the possible influence of self-selection bias on the magnitude of the effect of screening. 
Participation in the screening programme is voluntary. It is generally believed that 
women who decide to participate in screening have a different baseline risk of breast 
cancer mortality to those who decide not to participate. This difference in baseline risk, 
expressed as a ratio, can be used to adjust the screening estimate from a case-control 
study (odds ratio (OR)).9
Results from the literature on the direction of self-selection are, however, inconsistent. 
Friedman and Dubin found that women who refused screening were at lower baseline risk 
for breast cancer death compared to a control group. Adjustment for this difference in 
baseline risk causes a larger screening effect (OR further from 1.0). In contrast, Moss et al. 
found the opposite, which would result in a smaller screening effect (OR closer to 1.0).10-12 
It is to be expected that the factors underlying self-selection may be different in 
each country or even region that has implemented service screening. However, several 
studies have applied a correction factor based on estimates calculated from data from 
the Swedish and Canadian randomized controlled trials (RCT) by Duffy et al. instead of 
a country-specific or regionally determined selection factor.3,13 Based on the study by 
Duffy et al., we anticipated a higher breast cancer mortality rate in the non-screened 
women. Therefore, the correction factor for self-selection has been estimated as the ratio 
of the IBM rate in the non-screened women and the IBM rate of the not-invited women.9 
This ratio can then be applied to a formula to adjust the effect of breast cancer service 
screening on breast cancer mortality in a case-control study.9,14 
When nationwide screening is offered to all women in the target group, a well-defined 
control group is no longer available. In this situation, the only period from which a control 
group can be created is directly before the start of the implementation of a screening 
programme or during the implementation of the screening programme, when part of 
the target group is still not-invited. The purpose of this study is to estimate a correction 
factor for self-selection bias from the implementation period of the service screening 
programme in five regions of the Netherlands, using the incidence-based mortality 
method (IBM).15
Methods
Service screening in the Netherlands started in 1989, initially inviting women in the age 
group 50-69 biennially, and was fully implemented in 1997. In this period nine screening 
organisations were responsible for the organisation of the screening programme. In this 
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study we included five regions, namely Stichting Kankerpreventie en –screening Limburg 
(SKsL), Stichting Kankerpreventie IKA (SKP IKA), Stichting Bevolkingsonderzoek Noord-
Nederland (BBNN), Stichting Vroege Opsporing Kanker Oost-Nederland (SVOKON) and 
Stichting Bevolkingsonderzoek Borstkanker Zuidwest Nederland (SBBZWN). The regions 
were chosen based on their differences in urban and rural areas, and early and late 
implementation of the screening programme. These regions included 57% of the breast 
cancer patients in the age group 50-69 registered in the Netherlands Cancer Registry in 
the years 1990-1995.
An incidence-based mortality (IBM) rate can be calculated by dividing the number 
of breast cancer deaths resulting from incident breast cancer cases diagnosed in a 
specific period with the accompanying number of person-years. The calendar period for 
calculation of the IBM rate included the years 1990-1995. During the implementation 
phase of the Dutch screening programme, the female population in the targeted age 
group shifted from an uninvited population to an invited population, providing us with 
contemporaneous groups of not invited and invited but not screened women. 
In order to define the numerator of the breast cancer mortality rates, data of breast 
cancer patients aged 50-69 and diagnosed in the years 1990-1995 were collected from 
the Netherlands Cancer Registry. The patient data were linked to the screening registries 
of the five screening organisations to collect information on screening history and vital 
status. The data were also linked with the Cause of Death Registry held by Statistics 
Netherlands to obtain cause of death. The breast cancer patients were divided in three 
groups according to their screening status: not invited for screening before diagnosis 
(not-invited), invited and screened before diagnosis (screened), invited and not screened 
before diagnosis (non-screened). Breast cancer patients were defined as not screened 
after not participating in the most recent invitation to screening before diagnosis. We 
followed the breast cancer patients for breast cancer death for a maximum of 10 years 
after date of diagnosis. Screened patients were not followed since this group does not 
contribute to estimation of the correction factor.
In order to define the denominator of the breast cancer mortality rates, we calculated 
the person-years for the period 1990-1995 using aggregated data on the total number 
of invited women, the total number of screened women derived from the screening 
organisations, and the age-specific total population derived from Statistics Netherlands. 
In order to divide the person-years in a group of not-invited and a group of non-screened 
person-years, we calculated the number of person-years during the implementation 
period of the screening in each municipality separately. The municipality is the smallest 
possible unit of which the starting date of screening was known. The population data and 
starting date of screening were determined and used in a previous study by Otto et al.16 
Further details on the calculation of person-years along with an example can be found in 
the appendix. 
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table 5.1  Age at diagnosis and stage distribution for breast cancer patients divided to non-
screened and not-invited patients
Breast cancer patients Non-screened
N (%)
Not-invited
N (%)
Total 968 (100) 8979 (100)
Age at diagnosis
50-54
55-59
60-64
65-69
236 (24.4)
226 (23.4)
225 (23.2)
281 (29.0)
2475 (27.6)
1948 (21.7)
2082 (23.2)
2474 (27.5)
Stage*
0-1
2+
296 (32.2)
623 (67.8)
2847 (33.6)
5637 (66.4)
* for both groups 5% missing
Results
In total, 15 541 breast cancers were diagnosed in women aged 50-69 in the period of 1990-
1995. The complete number of person-years for this period was 5 199 451. Of the 8979 not-
invited breast cancer patients, 2631 died of breast cancer, whereas of the 968 not screened 
patients, 345 died of breast cancer. Table 5.1 shows patient characteristics of not-invited 
and non-screened women. The distributions of age at diagnosis (χ2=5.03, df=3, p=0.17) 
and stage at diagnosis (χ2=0.68, df=1, p=0.41) were comparable between both groups.
Data were available from five screening regions in the Netherlands. Poisson regression 
was used to test heterogeneity between the regions. The model which included the 
interaction terms of the regions fitted significantly better than the model without the 
interaction terms of the regions (χ2=0.03), which points towards a difference in the 
degree of self-selection in the five regions. 
Table 5.2 shows an example of the calculation of the IBM ratio in one region, namely 
the SVOKON region. The IBM rate in the non-screened women, 9.6 per 10 000 person-
years, is somewhat higher than the IBM rate for the not-invited women, 8.8 per 10 000 
person-years. Dividing those two IBM rates results in an IBM-ratio of non-screened versus 
not-invited of 1.08 (95% CI 0.85-1.37), indicating no self-selection in the SVOKON region. 
In Table 5.3, the correction factors and their 95% confidence intervals of all regions are 
given. As for the SVOKON region, the SBBZWN and SKsL region showed no difference in 
breast cancer mortality risk between the non-screened and not-invited women. The IBM 
rate ratio in the BBNN and SKP IKA region is lower than one, indicating a lower breast 
cancer mortality risk in the non-screened women. 
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table 5.2  Example of calculation of the incidence-based mortality (IBM) rates for non-
screened and not-invited women in the region of SVOKON
SVOKON Period 1990-1995
Non-screened           
 Incident cases
                         Breast cancer deaths
            Person-years
                 IBM / 10 000 PY
271
99
103 358
9.6
Not-invited                
 Incident cases
                         Breast cancer deaths
                                   Person-years
                                IBM /10 000 PY 
800
216
244 204
8.8
Rate ratio* (9.6/8.8)
(95% CI)                                            
1.08
(0.85-1.37)
* correction factor for self-selection, estimated by IBM rate non-screened / IBM rate not-invited
table 5.3  Correction factors for self-selection bias for five screening regions in the 
 Netherlands
Region Breast cancer deaths / person-years Rate ratio 
(95% CI)
Non-screened Not-invited
BBNN 36/73 412 702/917 668 0.64 (0.46 - 0.90)
SKP IKA 117/179 463 798/937 692 0.77 (0.63 - 0.93)
SKsL 39/63 341 189/282 716 0.92 (0.65 - 1.30)
SBBZWN 54/68 867 726/1 003 423 1.08 (0.82 - 1.43)
SVOKON 99/103 358 216/244 204 1.08 (0.85 - 1.37)
Discussion
The heterogeneity between the regions showed that even in a centrally organised 
screening programme regional differences can be found. Three of the five regions, 
namely the SBBZWN, SKsL and SVOKON regions, showed no difference in baseline risk in 
breast cancer mortality in women not participating to the Dutch screening programme 
compared to a not-invited population. In the BBNN and SKP IKA regions IBM ratios below 
1.0 were found, representing a lower baseline breast cancer mortality risk in non-screened 
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to not-invited women. These ratios can be used as regional correction factors for self-
selection bias for the odds ratio estimated in a case-control study to evaluate the impact 
of breast cancer screening on breast cancer mortality. Without correction in these two 
regions, the estimated breast cancer mortality reduction is slightly underestimated. 
Looking at the magnitude of the correction factors and their confidence interval, 
heterogeneity is most likely a result of the 0.64 (95% CI 0.46-0.90) in the BBNN region. 
Reasons why this region is different from the other regions are not known. An explanation 
may be the higher attendance rate (83.9% compared to 78.9% nationally17) and a difference 
in underlying background risks for breast cancer mortality; it is the most rural area 
in this study. Furthermore, the use of aggregated person years could have influenced 
the heterogeneity. Between 1990 and 1995 many municipal borders were redrawn and 
municipalities renamed.16 The precise division of the municipalities in the regions in this 
period is quite difficult to trace and some (differential) misclassification can have occurred. 
The reason for a somewhat lower rate ratio in the BBNN and SKP IKA regions is not 
known. Studies that explored reasons for non-attendance in the Netherlands mentioned 
mammograms taken outside the service screening programme, practical reasons, pain, 
no breast cancer in the family and breast self-examination as reasons for not accepting 
an invitation to screening.18,19 The possible association between these factors and a 
lower breast cancer mortality in non-screened women needs further exploration. A 
population survey performed in Australia also suggested that screening participants 
would have a slightly higher background risk of breast cancer than non-screened women. 
The participants were more likely to report a family history of breast cancer, a history of 
breast surgery, and previous use of hormone replacement therapy.7 Using a proxy for self-
selection bias like differences in risk factors or in incidence of breast cancer, is a way of 
coping with self-selection bias. However, caution is needed when interpreting the results. 
For example, it has been shown that equal breast cancer incidence in non-screened 
women and a control group does not necessarily lead to equal breast cancer mortality.12 
In the region of SKsL we calculated a correction factor of 0.92 (95% CI 0.65-1.30) in this 
study. In a previous case-control study in the same region, we calculated a correction 
factor of 0.84 (95% CI 0.58-1.21).20 There are two factors that might be responsible for 
this small change. First, we used a slightly different method to calculate the IBM-ratio. 
Instead of using date of diagnosis of each patient as start of follow-up, we had a start of 
follow-up time independent from date of diagnosis in the previous study. Second, a small 
difference in number of breast cancer deaths retrieved through linkage with the Cause of 
Death Registry of Statistics Netherlands could also be of influence. However, correction 
with these factors does not lead to a difference in impact of the breast cancer mortality 
reduction by breast cancer screening.
Our correction factors for self-selection calculated for the regions in the Netherlands 
differ from those used in other case-control studies. Duffy et al. calculated a correction 
factor for self-selection based on the data from RCTs of mammographic screening.9 
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This correction factor was 1.36, which represents a higher breast cancer mortality in the 
non-screened compared to the uninvited control group, and indicates a higher baseline 
mortality rate in the non-screened women compared to the screened women. The use of 
this correction factor is only justified when the relative mortality of the non-screened 
population and the population of uninvited women is the same in the programme at 
issue as observed in the previously published RCTs.9 In recent case-control studies, the 
correction factor of 1.36 has been used to correct the odds ratio for self-selection bias.3,13 
Puliti et al. and Gabe et al. estimated regional or country specific correction factors of 
1.11 and 1.17, respectively to correct the odds ratio.4,6 In line with their results, our study 
demonstrates that 1.36 cannot be interpreted as a constant correction factor. Rather a 
country-specific or regionally determined correction factor should be used. 
The application of date of diagnosis of each patient as start of follow-up was 
possible because we included non-screened and not-invited women only. When using 
a before-and-after the start of screening comparison for the effectiveness of screening, 
a date independent of diagnosis should be chosen to correct for possible lead time bias. 
Correction for lead time bias is only necessary if screened women are included in the 
comparison.14,21,22 
Based on our study, the IBM method is an effective tool for calculating the correction 
factor for self-selection bias in the Netherlands. This is supported by a Swedish study, 
where they also calculated regional specific correction factors for self-selection bias 
using the incidence-based mortality method.23 Our correction factor was based on breast 
cancer patients diagnosed in the period 1990 to 1995. Correction for self-selection bias 
of an estimated odds ratio for recent years would assume that the differential between 
the non-screened and not-invited women does not change over time. This assumption is 
inevitable, but is supported by the high and stable attendance rate in the Netherlands, 
which suggests that the non-screened women have not changed over time. 
In conclusion, the heterogeneity between the regions shows the necessity for 
calculating regional or country specific correction factors, even in a centrally organised 
screening programme. Looking at the range of IBM ratios in the five screening regions, the 
odds ratio estimated in a nationally conducted case-control study will show no change 
or a small increase in breast cancer mortality reduction after correction for self-selection. 
This indicates that self-selection is only a minor problem in the Netherlands.
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Appendix
Calculation of person-years
The calculated number of person-years were based on the number of invited women, 
the number of screened women and the age-targeted female population for each 
municipality in the five regions separately. The not-invited number of person-years were 
calculated by subtracting the number of invited person-years from the total person-years 
of the targeted population.
The person-years of invited women were estimated based on the number of invited 
women:
– year of the start of screening: half of the number of invited women
–  year+1: all invited women in the year of start of screening and half of the invited 
women in year+1
–  year+2: 95% of the total population of that year, assuming that 5% of the eligible 
population is not-invited
Adding up the number of invited person-years for every municipality for the total period 
of 1990-1995 resulted in the total number of invited person-years. 
In addition, the non-screened person-years were calculated by subtracting the screened 
person-years from the total number of invited person-years. 
The number of person-years of the screened women were based on the number of 
screened women:
– year of the start of screening: half of the number of screened women
–  year+1: all screened women in the year of start of screening and half of the screened 
women in year+1
–  year+2: half of the screened women in the year of start of screening, all screened 
women in year+1 and half of the screened women in year+2
Adding up the number of screened person-years for every municipality for the period 
1990-1995 resulted in the total number of screened person-years. 
An example is given for one municipality (Table 5.4 and Table 5.5).
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table 5.4  Number of invited women, number of screened women and the number of  
the age-targeted female population for each year separately for municipality X
Year 1990 Female population 50-69 N = 430
Year 1991 Female population 50-69 N = 438
Year 1992 Female population 50-69  N = 457
Invited women N = 437
Screened women N = 375
Year 1993 Female population 50-69  N = 464
Year 1994 Female population 50-69  N = 487
Invited women N = 473
Screened women N = 405
Year 1995 Female population 50-69  N = 510
table 5.5  Calculation of number of person-years for municipality X.  
Start date screening = 1-9-1992
Municipality X 1990 1991 1992 1993 1994 1995 Total
Total PY 430 438 457 464 487 510 2786
PY uninvited 430 438 238.5 27 24.3 25.5 1183.3
PY invited - - 218.5
(437*0.5)
437 462.7 484.5 1602.7
PY invited & screened - - 187.5
(375*0.5)
375 390 405 1357.5
PY invited & not 
screened
- - 31 62 72.7 79.5 245.2
PY=person-years
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Chapter 6
Case-referent study design and the impact  
on breast cancer mortality
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Abstract
Background  –  Recent case-control studies on the effectiveness of population-based breast 
cancer screening show differences in the magnitude of breast cancer mortality reduction. We 
investigated the role played by aspects of the case-control study design on these differences, 
e.g. the definition of cases and exposure to screening.
Material and Methods  –  We investigated six case-control studies conducted in East Anglia 
(UK), Wales, Iceland, central and northern Italy, South Australia and the Netherlands.
Results  –  The breast cancer mortality reduction in the different case-control studies ranged 
from 38% to 70% in the screened versus the non-screened women. We identified differences in 
design, e.g. the inclusion or exclusion of the first years of screening, and the correction factor 
for self-selection bias.
Conclusions  –  Overall, the design of the case-control studies was similar. The differences in 
the magnitude of breast cancer mortality reductions are therefore unlikely to be caused by 
variations in the design of the case-control studies. These differences must be due to other 
factors, like the organisation of the service screening programme and the attendance rate. 
The reduction in breast cancer mortality estimated in these case-control studies indicates 
that the impact of current mammographic screening is at least consistent with the effect 
reported by the former randomised screening trials.
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Introduction
Recently, several case-control studies have been conducted to estimate the effect of 
population-based service screening programmes.1-4 Their results show a decrease in 
breast cancer mortality which is at least consistent with the results of the randomised 
controlled trials (RCTs) conducted in the 1970s and 1980s. However, the magnitude of 
the effect, expressed in the odds ratio (OR), varies substantially between the different 
studies. We investigated the role of variations in the design of case-control studies on the 
differences in estimated effects of population-based breast cancer screening on breast 
cancer mortality. 
Population-based screening aims to identify each eligible woman in the target 
population in the area served by a screening programme and to personally invite them 
to each organisational round of screening.5 Continuous monitoring of the programme is 
required to better understand the positive results of screening and the negative outcomes, 
e.g. the number of false-positive screening outcomes. In addition, changes over time in 
baseline risk for breast cancer, screening methods and therapy also necessitate a periodic 
reassessment of efficacy. 
A case-control study is an efficient method for estimating the benefit of cancer 
screening.6 In 1986, Sasco et al.7 suggested that a routine case-control assessment of 
the functioning of a mass screening programme could be, or even should be, an integral 
part of ongoing evaluation. The use of a case-control study includes a number of 
methodological challenges, like the definition and selection of cases and controls, the 
definition of exposure to screening and self-selection bias.8 
Conducting a case-control study begins with defining the source population. A 
source population should include women who have died of breast cancer (cases), women 
who have not died of breast cancer (controls) and population-based screening must be 
available to all members of the source population.9 The use of death certificates is a 
valid way of classifying breast cancer as the underlying cause of death for the cases.10-12 
Controls should be selected from the source population that generated the cases. 
Furthermore, they should be free of breast cancer at the time of diagnosis of the case 
and should be alive at time of death of the case.9,13 Care must be taken to ensure that the 
cases and controls have an equal opportunity for screening.8 After identifying the cases 
and controls, the screening history of the cases is compared with the screening history of 
the controls. If screening is effective, the cases have had less exposure to screening than 
the controls. 
Self-selection bias has received a great amount of attention when using case-control 
studies for measuring the effectiveness of screening. It refers to the possible difference 
in baseline risk for breast cancer death a priori for women who accept the invitation 
to screening compared with those who do not accept the invitation to screening.8 In 
the literature, contradictory results have been noted with regard to the direction and 
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magnitude of self-selection. Where Friedman and Dubin found that women who accepted 
screening were at higher baseline risk for breast cancer mortality compared with a control 
group, Moss et al. found the opposite.8,14,15
Material and methods
Literature search
A PubMed search was carried out for the period 2000 to 2010 to identify recent publications 
written in English on case-control studies that assessed the effect of a breast cancer 
service screening programmes in steady state on breast cancer mortality. A study was 
included if it fulfilled the following conditions: the case-control studies had to be based 
on population-based screening programmes and had to include breast cancer deaths 
occurring in the steady state of screening, which we defined as breast cancer deaths after 
the year 2000. 
The following search strategy was used: ‘mass screening’ [mesh] and (‘case-control 
studies’ [mesh] or ‘case–referent’) and ‘breast neoplasms/epidemiology’ [mesh]. We 
manually searched the bibliographies of recent reviews of the evaluation of service 
screening on breast cancer mortality for additional references.16-18 In total, 121 studies 
were retrieved. Titles and, if necessary, abstracts found through the search strategy were 
evaluated for potential relevance. 
Six articles of recent case-control studies in population-based service screening 
countries were identified: East Anglian region (UK) (Allgood et al.1), Wales (Fielder et al.19), 
Iceland (Gabe et al.2), the Netherlands (Paap et al.20), central and northern Italy (Puliti et 
al.3), and South Australia (Roder et al.4). From this point on, we refer to these studies using 
the name of the first author. 
Design aspects of case-control studies
We focused on five design aspects of the selected case-control studies, which could 
influence the magnitude of the estimated ORs: the source population, the selection of 
cases, the selection of controls, the definition of exposure to screening and correction for 
potential selection bias.8,13,21 If information was not available in the paper, we contacted 
the first author. The design of the six case-control studies is presented in Figure 6.1. In 
Figure 6.1, a timeline represents the change from a not-invited population to an invited 
population (source population) after the start of the implementation of a screening 
programme. From this invited population, a case and control were selected who both 
have a screening history from which the effectiveness of breast cancer screening can be 
estimated. 
Source population. According to the source population, we looked at differences in the 
age of invitation, e.g. women aged 40–49 years are not included in every country. This 
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figure 6.1  Design of the case–control studies for screening. Inv1, invitation 1 of case and 
control; Inv2, invitation 2 of case and control; N-Inv, not-invited women; Inv, invited women.
can lead to a different estimate of the impact of the screening programme. It is likely that 
breast cancer screening has less impact on breast cancer mortality in women aged 40–49 
years compared with those aged 50–69 years. Including women aged 40–49 years in the 
analysis will therefore result in an OR closer to 1.
Selection of cases. A distinction is made between primary breast cancer deaths (breast 
cancer as underlying cause of death) and secondary breast cancer deaths (breast cancer 
present at death). Inclusion of primary breast cancer deaths alone can give different 
results than when secondary breast cancer deaths are included; in this last case, the 
effect of screening is probably diluted. 
An optimal screening effect is not achieved in the first years of screening because 
prevalent screen-detected cases benefit less.22 Prevalent screen-detected cases are women 
diagnosed in the first round of screening or in a woman’s first test at a subsequent 
round.23 Therefore, they dominate the first years of the implementation of screening 
programmes. Excluding breast cancer diagnosis and breast cancer deaths during the first 
years of implementation from the case-control study results in an estimate of the steady 
state of the screening programme.
Selection of controls. For the controls, we focused on the methods used to ensure that 
they had the same opportunity for screening as the cases. 
Definition of exposure to screening. The time window for including screening history 
should be limited to the detectable preclinical period (DPCP).8,24 Including screening 
examinations outside the DPCP can distort the effect of screening. Therefore, differences 
exposure to screening
selection of cases
selection of controlstime ->        Start implementation
outcome
Breast cancer diagnosisBirth
Birth Control
(pseudodiagnosis)
(No breast cancer)
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N-Inv Inv                source population
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in the time window of screening exposure can lead to differences in outcome. Etzioni and 
Weiss21 found that underestimation of the duration of the DPCP leads to greater bias than 
overestimation. Both are expected to bring the OR closer to 1.21,25
Correction for selection bias. In the six case-control studies, we checked which method 
and correction factor was used to correct for self-selection bias, e.g. the method and 
correction factor of Duffy et al.26 Duffy et al. calculated a correction factor of 1.36 based 
on the relative rate of breast cancer deaths in non-attenders in the Two-County, Malmö, 
Gothenburg, Stockholm and Canadian national breast screening RCTs compared with 
women in the control arm of these RCTs. 
Adjustment for socioeconomic status (SES) can contribute partly to the amount of self-
selection bias.19 As there is a correlation between SES and breast cancer risk, differences 
in SES in screened and nonscreened women are likely to have an influence on the effect 
estimate.27,28
Results
The start of the service screening in the countries of the six identified case-control 
studies was between 1987 and 1990. Table 6.1 provides details of the relevant background 
information of the service screening in each country. Table 6.2 shows an overview of the 
results of the analysis of women who attended screening compared with those who 
did not attend screening. The mortality reduction ranged from a minimum of 38% in 
Wales (OR 0.62, 95% confidence interval (CI) 0.47–0.82) to a maximum of 70% in the 
Netherlands (OR 0.30, 95% CI 0.14–0.63). These results do not include any corrections for 
self-selection.
Source population. All programmes invite women aged 50–69 years, with the exception 
of Wales, which invites women aged 50–64 years (Table 6.1). The UK and Australia allow 
women over 70 years to come to the screening, whereas the Netherlands actively invites 
women aged up to 74 years. Women aged 40–49 years are actively invited in Iceland and 
are allowed to take part in the service screening in Australia.
Selection of cases. Four case-control studies included primary breast cancer deaths only. 
Allgood and Fielder also included secondary breast cancer deaths (Table 6.3). The ORs 
calculated by Allgood and Fielder, 0.35 and 0.62, respectively, were no different to the 
other four studies. Allgood, Paap and Roder restricted the years of breast cancer diagnosis 
and the time period of breast cancer deaths, thereby excluding the prevalent cases in the 
years of the implementation of the screening programme. Allgood and Paap showed the 
lowest ORs of all case-control studies.
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Selection of controls. Five case-control studies used a pseudo diagnosis for each control, 
which was equal to the date of diagnosis of that control’s matched case (Allgood, Fielder, 
Gabe, Puliti and Roder). To ensure an equal opportunity for screening, in the design phase, 
Puliti postponed the pseudo diagnosis for the controls matched to screen-detected cases 
by 1 year to compensate for lead time in the screen-detected cases.29 Fielder did the same, 
but then as a secondary analysis and with a postponement of 18 months. This had no 
effect on the OR. Paap corrected for opportunity for screening by making sure that the 
control was invited for the same screening round from which the index invitation of the 
case emerged. In Gabe’s study, the correction for opportunity was based on a calculation 
described by Duffy et al.30
Exposure to screening. Primary analysis of the case-control studies was based on the 
complete screening history before diagnosis (case)/pseudo diagnosis (control); the ever/
never comparison (Figure 6.1). Paap used an index invitation for exposure, which was 
defined as the invitation date closest to the date of diagnosis of the case.
Correction for selection bias. In all articles, corrections for self-selection bias were made 
using the method described by Duffy et al.26 (Table 6.4). Allgood and Fielder used the 
same correction factor as Duffy et al. (1.36). Roder mentioned in the discussion that the 
adjusted OR for self-selection using Duffy’s formula et al. would be around 0.70, thus 
indicating a 30% mortality reduction instead of 41% reduction with no correction for 
self-selection. 
Instead of using the correction factor of 1.36, Gabe, Puliti and Paap used an area-
specific correction factor, which were 1.17, 1.11 and 0.84, respectively. Gabe (personal 
communication with first author) calculated their correction factor as being the relative 
risk of breast cancer death for non-attenders compared with the uninvited population 
from the RCTs as estimated in the paper by Duffy et al.26 Puliti used a group of not-yet-
invited women, which was available because of the long implementation period of the 
service screening in Italy. They compared the OR in the never respondents with that in the 
not-yet-invited. Paap used the incidence-based mortality method as a tool to calculate 
a correction factor for self-selection.23 They calculated the incidence-based mortality 
for a group of women not-yet-invited during the implementation period of screening 
and compared this with the incidence-based mortality for the not-screened women in 
the same period. Corrections for SES were carried out by Allgood, Fielder and Roder and 
showed no alterations to the ORs.
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Discussion
Our study focused on the impact of differences in the design of recent case-control 
studies on the effect of breast cancer mortality in population-based breast cancer 
screening programmes. Although we found many minor differences in the set up of the 
six case-control studies, the overall design was quite similar. However, the range of the 
mortality reductions in the different case-control studies was large: from 38% reduction 
in Wales to 70% reduction in the Netherlands. 
Looking at the differences in invited age groups, women aged 40–49 years were only 
included in the studies by Gabe and Roder. Roder included a stratified analysis of the 
effect of different age groups, which showed an OR of 1.18 in the age group <50 years and 
an OR of 0.54 (Table 6.2) in the age group 50-69 years. The change from an OR of 0.59 for all 
ages to an OR of 0.54 for the age group 50-69 years indicates that age of invitation plays 
no key role in the difference of the estimated OR in Australia compared with the other 
countries. A reason for this could be that there are fewer cases in the 40-49 age group 
than in those aged 50-69 years. Therefore, the OR of 0.59 will mainly consist of results for 
the latter group. Gabe did not show any age-specific results, but a large change in OR is 
not expected for the proportionally small numbers found in the younger age group. 
A difference between the screening case-control studies is the inclusion or exclusion of 
the first years of screening. Analysis of the steady state gives lower ORs than the studies 
which included the first rounds of screening. This is also demonstrated in Fielder’s study, 
where the OR including diagnosis in the early years of screening was 0.62 (95% CI 0.47-
0.82) and the OR excluding diagnosis in the early years of screening was 0.49 (95% CI 
0.36-0.66). Excluding the early years of screening in the studies by Gabe and Puliti will 
probably bring the effect on breast cancer mortality closer to the effect found by Allgood 
and Paap. Roder, however, did not find a large impact of the service screening programme 
compared with Allgood and Paap. This could perhaps be due to the lower attendance rate 
in Australia (57%) compared with the UK (75%) and the Netherlands (82%). 
All case-control studies aimed to ensure an equal opportunity for screening for both 
the controls and the cases. Fielder showed no alteration in the OR. A sensitivity analysis 
carried out by Puliti for time lags of 6 months and 1.5 years instead of 1 year showed only 
small alterations in the OR. Gabe showed a change in the OR from 0.59 (95% CI 0.41-0.84) 
to 0.51 (95% CI 0.31-0.86) after correction for opportunity for screening, thus only a small 
change in the OR. Gabe based his correction on a method developed by Duffy et al.30 
Using the correction method of Duffy et al. will already partly adjust for the prevalent 
screens in the first years of screening. The study by Duffy et al. also corrected the OR 
of Fielder for opportunity for screening using the same method, which did not lead to a 
change in the OR. These results show that the impact of opportunity for screening on the 
magnitude of the OR is limited. 
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The analyses for exposure to screening are similar in all case-control studies except Paap, 
who used exposure to the index invitation as their primary analysis instead of using the 
ever/never comparison. The screening history should be limited to the period when the 
cancer is potentially detectable on the mammogram – in the DPCP. The exact duration of 
the DPCP is not known, but in the future, when service screening has been running for a 
longer period, the ever/never comparison will overestimate the length of the DPCP, which 
would cause a false reduction of the size of the benefit of screening.21,25 By only using the 
index invitation, Paap has probably underestimated the length of the DPCP. Extending the 
exposure to screening, to the invitation preceding the index invitation, resulted in a small 
change in mortality reduction from 70% to 73% (OR 0.27, 95% CI 0.12-0.62). 
By correcting the OR for self-selection bias using the correction factor of 1.36 calculated 
by Duffy et al., two assumptions are made: the relative mortality in the noncompliers 
compared with the not-yet-invited is the same in the service screening programmes as 
it is in the RCTs and self-selection in Sweden and Canada is the same as in the countries 
where the case-control studies are carried out. This may not hold for most populations. 
For example, a high attendance rate, like in the two-county trial, will make the group of 
women not attending the screening more special.26 The area-specific calculated correction 
factors did not indicate a very high impact of self-selection on service screening compared 
with no impact of self-selection (OR 1). The correction factor for Italy calculated from 
not-yet-invited cases and never-screened cases was 1.11 (95% CI 0.87-1.40), the correction 
factor of Gabe was 1.17 (95% CI 1.08-1.26) and the correction factor of Paap calculated from 
the incidence-based mortality method was 0.84 (95% CI 0.58-1.21). 
The adjustments for SES had no effect on the ORs of the case-control studies, 
indicating a minor influence of self-selection bias on the effect estimate of screening 
on breast cancer mortality as well. Furthermore, to assist the interpretation of the case-
control study, Roder also included a population survey to identify potential differences in 
risk profiles by screening participation. This survey showed that predictors for screening 
participation were a higher number of first-degree female relatives with a history of breast 
cancer, exposure to hormone replacement therapy and a history of breast surgery for any 
reason. This suggests that screening participants may have a higher background risk for 
breast cancer than non-participants. On the other hand, Lawrence et al. showed that the 
10-year relative survival rate in never attenders (51.9%) was lower than the survival rate in 
women diagnosed before invitation (67.6%). This was in contrast with the survival rate of 
occasional non-attenders, who had a relative survival rate of 66.9%.31 This indicates that 
the correction factor for self-selection is influenced by the type of non-attender as well. 
So it seems that the correction factor of 1.36 is not valid in other screening programmes 
to correct for self-selection and should not be used in future case-control studies. Instead, 
region- or country-specific correction factors for self-selection should be estimated. More 
emphasis should be placed on exploring methods like the incidence-based mortality 
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method to calculate differences in the underlying breast cancer mortality risk in the 
screened and not-screened populations to determine the impact of self-selection in the 
service screening.
Overall, the design of the six case-control studies was similar. However, inclusion of 
the first years of screening and the correction factor used to correct for self-selection bias 
can probably explain some of the differences in the magnitude of the effect in the recent 
population-based case-control studies. Other factors must influence the ORs of the case-
control studies, e.g. differences in attendance rate, in the quality and organisation of the 
screening programme and in the quality of treatment. The range of obtained mortality 
reduction was 38%-70% in the six case-control studies (25%-76% after correction for 
self-selection). This indicates that the impact of current mammographic screening is at 
least consistent with effect (25%-30%) reported by the former randomised screening 
trials.
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Chapter 7
Effectiveness, the case-referent design 
and what’s next 

e f f e c t i v e n e s s ,  t h e  c a s e - r e f e r e n t  d e s i g n  a n d  w h a t ’ s  n e x t   87
Breast cancer screening programmes have been implemented in many Western countries 
to reduce breast cancer mortality. However, the benefits achieved by these programmes 
are still an extensive topic of debate.1,2 Very recently the discussion on the effectiveness of 
screening has been given impetus as a result of negative articles published in high impact 
journals.3-5 The opponents of breast cancer screening state that the mortality reduction 
achieved by screening is only minor and they question the balance of benefits and harms. 
The results of this thesis show that screening brought about a significant 58% reduction 
of breast cancer mortality in screened versus unscreened women (58% reduction, 95% CI 
47%-67%), indicating that the Dutch breast cancer screening programme is highly effective. 
 We have shown that the case-referent study is a valid and feasible tool to monitor the 
association between breast cancer screening and breast cancer mortality, if comparability 
between screened and unscreened women is guaranteed. It is essential to correct the 
odds ratio emerging from the case-referent study for self-selection bias, if present. To this 
end, we used the incidence-based mortality method to calculate the differential in breast 
cancer mortality between the group of unscreened and the group of not-invited women. 
Validity of the case-referent design
We believe that the case-referent design is the most appropriate methodology to 
estimate the actual benefit of the current screening programme. However, not everyone 
is convinced of the validity of the results from the case-referent design. This is illustrated 
by a response from a Journal Editor based on a recent submission: ‘… randomized designs 
will likely generate much more robust and unbiased estimates of effect than case-control 
or cohort studies’. Or even worse, in a reply letter to a case-referent study conducted 
in Nijmegen, the method used was described as flawed.6 Randomised controlled trials 
(RCTs) are considered the ‘gold standard’ research design. However, after nationwide 
implementation of a screening programme, only observational designs are available for 
estimating the effectiveness of screening programmes. It has been demonstrated that 
well-designed case-referent studies provide equally valid results regarding the magnitude 
of breast cancer mortality reduction.7-11 
In RCTs the effect of screening is measured by comparing women invited versus 
women uninvited to the screening programme (intention to treat estimate). The 
magnitude of the effect estimate in the RCTs is influenced by the attendance rate of the 
invited women. In case-referent studies screened women are compared with unscreened 
women, thereby resulting in a larger effect estimate of screening. The odds ratio resulting 
from a case-referent study can be translated into an intention to treat estimate. In 
the Netherlands translation to an intention to treat estimate based on an attendance 
rate of 80% still results in a larger mortality reduction compared to the early trials 
(48% reduction, 95% CI 39%-56%; Chapter 4). This could be explained by improvements in 
the quality of service screening over time and a larger combined effect of early detection 
and improved treatment.12  
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In the scientific literature, many papers have been written on the methodology of case-
referent studies for the evaluation of cancer screening.13-16 International agreement has 
been reached about the correct methodology for conducting a case-referent study, as 
demonstrated by the comparability of the designs of recently conducted case-referent 
studies (Chapter 6).17 Some differences in the design were identified, of which the 
most important were the in or exclusion of the first years of screening and the source 
population from which the correction factor was derived to address self-selection bias.
In Chapter 5 we showed that for the five large screening regions included in our studies 
the magnitude of self-selection varied.18 This illustrates that the estimation of a national 
and even region specific estimate for self-selection is an important part of conducting a 
case-referent study. For the five regions, we demonstrated that self-selection bias only 
plays a minor role in the overall effectiveness estimate of breast cancer screening. We 
advise to estimate regional specific correction factors for future regional evaluations in 
the Dutch regions not included in this study. 
Furthermore, confounding bias of the odds ratio can occur when prevalence of a risk 
factor for breast cancer death is imbalanced across the compared groups. Age is strongly 
related with both the occurrence of breast cancer death and screening participation. 
It is therefore necessary to adjust the effect estimate for age by matching beforehand 
or in the analysis afterwards. In this thesis we matched for age, thereby correcting for 
the influence of this confounder. Other than age there was no background information 
available on other possible risk factors for breast cancer in our dataset. Risk factors like 
mammographic density, socioeconomic status and obesity could theoretically distort 
the relation between breast cancer screening and breast cancer mortality. However, we 
demonstrated that residual confounding after adjustment for age is a minor issue in the 
evaluation of screening programmes.19 Therefore, we assume that any other confounding 
factors will not greatly affect the estimated benefit of the screening programme.
Another point for discussion is that some researchers are not convinced that the use 
of primary breast cancer death as an endpoint is a reliable measure.20,21 In our studies 
the outcome measure was primary breast cancer death based on death certificates 
documented in the Cause of Death Registry. Based on evidence from different countries, 
the Health Council of the Netherlands concluded in 2002 that the use of death certificates 
is valid for use as an end point for the evaluation of the screening programme, as the 
misclassification rate is modest and is not affected by mode of detection.22-26 
What’s next?
The case-referent design is an appropriate monitoring tool for future periodical 
evaluations of breast cancer screening effectiveness. Conducting a case-referent study 
will become easier with the current availability of the nationwide databases of the 
Netherlands Cancer Registry and the screening organisations. The introduction of a 
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nationwide unique identifier, the Civil Service Number (Burger Service Nummer, BSN) in 
the registries of screening organisations, cancer registry and Statistics Netherlands will 
also greatly improve the linkage of individual data from different registries to each other, 
both in terms of efficiency as well as quality due to less uncertainty about proper linkages. 
Unfortunately, at this moment The Dutch Personal Data Protection Act (Wet Bescherming 
Persoonsgegevens, WBP) states that the BSN may not be used for research purposes.
In addition, the case-referent design should be used if changes and improvements 
over time in the field related to breast cancer screening are expected to have an influence 
on breast cancer mortality, like changes in incidence of breast cancer or improvements 
in treatment. The odds ratio, emerging from the case-referent study is a result of the 
combination of early detection followed by appropriate treatment. Assuming that the 
applied treatment depends on the stage of disease at diagnosis, treatment is somehow 
an intermediary in the relation between screening and breast cancer mortality. If future 
improvements in treatment come to a point where breast cancer can be treated more 
effectively at any stage, the difference in stage specific survival will decline, which will 
have an effect on the estimated odds ratio.27
A current example of improved technology is the implementation of digital 
mammography in the Dutch screening programme, which started in 2008 and was 
completed in 2010. It is expected that digital screening will lead to further reduction of 
breast cancer mortality, because of an improved detection rate. This improvement is 
most prominent in the initial screening examinations, i.e. for the youngest women of the 
screening population.28-30 Improvements in the screening programme need a long follow-up 
time to measure further reductions in breast cancer mortality as a result of earlier cancer 
detection. Therefore, a period of ten years is required between the conducted case-referent 
studies. Further to the case-referent studies conducted in this thesis, this would mean 
that in a future case-referent study, cases are included who died up to and including 2015. 
Some of these cases will have been screened digitally and some analogously, because the 
majority of the cases will have been diagnosed in the ten years before they died. 
Self-selection bias
All future case-referent studies should address the application of a correction factor for 
self-selection. For our calculations we used data from the implementation period of 
the screening programme in the Netherlands. Only before nationwide implementation 
is it possible to compare a group of not screened women with a group of not-invited 
women. Thus in the Netherlands, no more recent correction factors for self-selection can 
be estimated. By using the correction factor for the period 1990-1995, the assumption is 
made that the differential in baseline mortality risk has not changed over time. Given 
the stable attendance rate in the Netherlands we expect this assumption to be valid. 
However, future changes in attendance rate or risk factors which might influence the 
differential in breast cancer mortality risk between screened and unscreened women 
might change the plausibility of the correction factors based on the years 1990-1995.
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There are two options for indicating whether these correction factors remain plausible 
over time. The differential of the annual incidence rates of breast cancer for screened 
and unscreened women should remain unchanged. This differential can be used as 
a monitoring tool to look for major changes. Another option for the evaluation of the 
baseline risks for breast cancer death of screened and unscreened women, could be the 
collection of information on risk factors for breast cancer mortality, like the registration 
of mammographic density following screening examinations.31,32 Differences in incidence 
and risk factors do not necessarily lead to an equal translation to differences in breast 
cancer mortality between screened and unscreened women, and the results need to 
be interpreted with caution. For example, it has been shown that equal breast cancer 
incidence in unscreened women and a not invited control group based on data from the 
United Kingdom trial does not necessarily lead to equal breast cancer mortality, because 
of a tendency for breast cancers in unscreened women to have a poor prognosis relative 
to those in the comparison population.11 A further understanding of these possible 
indicators for self-selection bias and coping with the problems they raise is essential for 
the future use of case-referent studies.
Communication
The information resulting from a case-referent study is relevant for communicating the level 
of risk reduction a woman may expect when participating in the screening programme.9,33 
The results of our study add valuable and not previously known information about this 
risk reduction in the Netherlands: women who attend the Dutch screening programme 
halve their risk of dying from breast cancer (OR = 0.42, 95% CI 0.33 to 0.53). 
To understand the impact of the screening programme absolute numbers are generally 
more easy to understand than the relative effect measure coming from the case-referent 
design. Translation of the odds ratio estimated in this thesis to an absolute number needs 
careful consideration, because it will be based on a number of assumptions.34,35 Moreover, 
graphical displays of information instead of numerical data may substantially improve 
comprehension of risk.36,37 The research field of communication strategies in screening 
programmes is large and beyond the scope of this thesis.38,39 
Most importantly, communicating the benefit of the Dutch screening programme 
expressed as the effect estimate of the case-referent design needs to be done in a clear, 
proper and balanced way to the women invited to the screening programme.
A well matched pair!
Based on our results, we conclude that the case-referent design is the preferred tool for 
monitoring breast cancer mortality reduction due to screening with the provision that 
a reliable correction for self-selection bias is available. For the evaluation of the Dutch 
breast cancer screening programme now and in the future, breast cancer screening 
effectiveness and the case-referent design are a well matched pair.
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The Dutch breast cancer service screening programme has now been running for 20 years. 
The current breast cancer mortality reduction can differ from results generated from 
the pilot programmes and randomised controlled trials on which the programme was 
implemented. To estimate the benefit of screening, i.e. the preventable fraction of breast 
cancer deaths, the case-referent design is an appropriate tool, if specific methodological 
complexities are allowed for. As such, the case-referent study was tested as a monitoring 
and evaluation tool for assessing the ongoing programme. To address this, we estimated 
the impact of screening mammography at both regional and national level, using 
individual data directly linking screening history with breast cancer death. In addition, 
we calculated regional correction factors for self-selection bias, estimated with data 
from the implementation phase of the screening programme, using the incidence-based 
mortality method. Furthermore, we investigated whether differences in the designs 
used explained the differing mortality reductions from recently conducted case-referent 
studies. Because the impact of screening on mortality is dependent on the incidence in 
the population, we estimated changes in lifetime risk over the past two decades.
Lifetime risk
The lifetime risk represents the average risk at birth that a Dutch woman will develop 
breast cancer or die from breast cancer during her lifetime. We found that the lifetime risk 
for developing breast cancer (both invasive and carcinoma in situ) has increased from 1 in 
10 in 1989 to 1 in 7 in 2003. The risk of dying from breast cancer has decreased respectively 
from 1 in 22 to 1 in 26. 
Effectiveness
Breast cancer screening trials conducted in the 1970s and 1980s resulted in a breast 
cancer mortality reduction of 25-30% in those offered mammographic screening. On the 
basis of these trial results, mammographic screening programmes were implemented 
in many Western countries in the 1990s to reduce the burden of breast cancer mortality. 
Nevertheless, the benefits are still subject to debate: whether the mortality reduction 
is large enough to justify the harms of screening. To assess the effect of screening on 
breast cancer mortality reliably, it is necessary to directly link a woman’s cause of death 
and her screening history. We applied the case-referent design to evaluate the effect of 
the current Dutch population-based screening programme. The odds ratio (OR), emerging 
from the case-referent study, was adjusted for self-selection bias using regional correction 
factors for the difference in baseline risk for breast cancer death between screened and 
unscreened women.
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In a case-referent study conducted in the province of Limburg, analysis of the data 
showed a breast cancer mortality reduction of 70% in the screened versus unscreened 
women (OR = 0.30, 95% CI 0.14 to 0.63]. After correction for self-selection bias, the effect 
of screening increased to 76% (OR = 0.24, 95% CI 0.10 to 0.58]. In the nationwide case-
referent study, we found that attending the screening programme resulted in a 58% 
reduction in breast cancer mortality (OR = 0.42, 95% CI 0.33 to 0.53). In conclusion, the 
current Dutch breast cancer screening programme is achieving a substantial reduction in 
breast cancer mortality.
Self-selection bias
A problem associated with case-referent studies is the possible influence of self-
selection bias on the magnitude of the effect of screening. Participation in the screening 
programme is voluntary. It is generally believed that women who decide to participate in 
screening have a different baseline risk of breast cancer mortality to those who decide 
not to participate. This difference in baseline risk, expressed as a ratio, can be used to 
adjust the screening estimate from a case-control study (OR). Using the incidence-based 
mortality method (IBM), a correction factor for the potential influence of self-selection 
can be derived from a group of unscreened women and a group of not-invited women. 
Incidence-based breast cancer mortality rates according to screening status were 
calculated for five screening regions in the Netherlands. Heterogeneity between the 
regions was shown, which stresses the importance of a country- and/or region-specific 
estimate of self-selection. Adjusting for self-selection bias in the regional case-control 
studies would not change the breast cancer mortality reduction in three regions and 
would result in an even larger effect in two regions. Looking at the range of IBM ratios the 
overall influence of self-selection in the Netherlands is minor.
Differences in case-referent designs
Recent case-referent studies on the effectiveness of population-based breast cancer 
screening show differences in the magnitude of breast cancer mortality reduction. 
We investigated the role of variations in the design of the case-referent study on the 
differences in estimated effects. We included six case-referent studies conducted in 
East Anglia (UK), Wales, Iceland, central and northern Italy, South Australia and the 
Netherlands. 
The breast cancer mortality reduction in the different case-referent studies ranged 
from 38% to 70% in the screened versus the unscreened women. Although we found 
many minor differences in the set up of the six case-referent studies, the overall design 
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was similar. Inclusion of the first years of screening and the correction factors used for 
self-selection bias probably explain some of the differences in the magnitude of the 
effect estimates. However, other factors, e.g. the organisation of the service screening 
programme, will have an effect on the variation in mortality reductions. 
Breast cancer screening effectiveness and the case-referent 
design: a well matched pair
The results of this thesis show that screening, i.e. early detection and treatment, brought 
about a substantial reduction of breast cancer mortality in screened versus unscreened 
women, indicating that the Dutch breast cancer screening programme is highly effective 
in reducing breast cancer mortality (OR = 0.42, 95% CI 0.33 to 0.53). We have shown that 
the case-referent study is a valid and feasible tool to monitor the association between 
breast cancer screening and breast cancer mortality, if comparability between screened 
and unscreened women is guaranteed. Therefore, it is essential to correct the odds ratio, 
emerging from the case-referent study, for self-selection bias, if present. We showed that 
self-selection bias only plays a minor role on the overall effectiveness estimate of breast 
cancer screening.
The case-referent design can be used for future evaluations if changes and 
improvements over time related to breast cancer screening are expected to have an 
influence on breast cancer mortality, like changes in incidence or improvements in 
treatment. All future case-referent studies should address the application of a correction 
factor for self-selection. For the Netherlands, no more recent correction factors can be 
estimated. Future changes might influence the plausibility of the correction factors 
based on the years 1990-1995. Therefore, an understanding of potential indicators for self-
selection bias is essential for the future use of case-referent designs. 
For the evaluation of the Dutch breast cancer screening programme now and in the 
future, breast cancer screening effectiveness and the case-referent design are a well 
matched pair.

Samenvatting
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Op basis van de resultaten van wetenschappelijke studies uit de jaren ’70 en ’80 is 
besloten om in Nederland het bevolkingsonderzoek naar borstkanker in te voeren. 
De implementatie hiervan is gestart in 1989 en landelijke dekking werd bereikt in 
1996. Nu het programma twintig jaar bestaat willen we weten hoe groot de daling van 
borstkankersterfte door het landelijk bevolkingsonderzoek naar borstkanker is. Om 
dit effect te kunnen bepalen is het patiëntcontroleonderzoek een geschikte methode. 
Bij deze complexe onderzoeksmethode dient men rekening te houden met een aantal 
methodologische aspecten. In dit proefschrift gaan wij hier uitvoerig op in en onderzoeken 
wij hoe bruikbaar het patiëntcontroleonderzoek is voor het monitoren en het evalueren 
van de invloed van het bevolkingsonderzoek naar borstkanker op de borstkankersterfte 
in Nederland.
Bij het patiëntcontroleonderzoek vergelijken wij de borstkankersterfte in een groep 
gescreende vrouwen ten opzichte van de borstkankersterfte in een groep niet-gescreende 
vrouwen. We hebben individuele gegevens over deelname aan het bevolkingsonderzoek 
gekoppeld aan individuele gegevens over borstkankersterfte. Met deze gegevens hebben 
we zowel regionaal als nationaal het effect van screening bepaald. Daarnaast hebben 
we, met behulp van gegevens uit de implementatieperiode van het bevolkingsonderzoek, 
regionale correctiefactoren uitgerekend om te kunnen corrigeren voor eventuele 
zelfselectiebias. Zelfselectiebias kan optreden als de groep vrouwen die deelneemt aan 
het bevolkingsonderzoek een ander basisrisico op borstkankersterfte heeft dan de groep 
vrouwen die niet deelneemt. Verder hebben we onderzocht of verschillen in de  methode 
van het patiëntcontroleonderzoek kunnen leiden tot de internationale verschillen in 
gevonden daling in borstkankersterfte. De werking van een bevolkingsonderzoek is 
ook afhankelijk van de incidentie in een populatie. Daarom hebben we eerst gekeken 
naar veranderingen in de kans op borstkanker sinds de invoering van het Nederlands 
bevolkingsonderzoek naar borstkanker.
De kans op borstkanker
Het risico dat een Nederlandse vrouw bij geboorte heeft om gedurende haar leven 
borstkanker te krijgen kan worden bepaald met behulp van populatiegegevens. De kans 
om borstkanker (zowel invasief als in situ carcinoom) te krijgen is gestegen van 1 op 10 in 
1989 naar 1 op 7 in 2003. De kans om aan borstkanker te overlijden is gedaald van 1 op 22 
naar 1 op 26.
Het effect van screening op de sterfte aan borstkanker
In de trials in de jaren ’70 en ’80 is een daling in borstkankersterfte van 25-30% 
gevonden bij de groep vrouwen die was uitgenodigd voor mammografische screening. 
Op basis van deze studies zijn er in het begin van de jaren ’90 in veel Westerse landen 
screeningsprogramma’s ingevoerd. Om de beoogde sterftedaling betrouwbaar te 
kunnen bepalen is het belangrijk om de doodsoorzaak van een vrouw te koppelen aan 
haar deelname aan het bevolkingsonderzoek. Bij het patiëntcontroleonderzoek wordt 
de deelname van aan borstkanker overleden vrouwen vergeleken met de deelname van 
vrouwen die voor screening zijn uitgenodigd. Dit resulteert in een odds ratio (OR), de 
uitkomstmaat van het patiëntcontroleonderzoek. De OR hebben we gecorrigeerd voor 
eventuele zelfselectiebias met regionale correctiefactoren. 
Het patiëntcontroleonderzoek uitgevoerd in de provincie Limburg liet een sterftedaling 
van 70% zien bij de gescreende vrouwen ten opzichte van de niet-gescreende vrouwen 
(OR = 0.30, 95% CI 0.14-0.63). Na correctie voor zelfselectiebias was de sterftedaling 76% 
(OR = 0.24, 95% CI 0.24-0.58). In het landelijke patiëntcontroleonderzoek vonden we na 
correctie voor zelfselectiebias een sterftedaling van 58% (OR = 0.42, 95% CI 0.33-0.53). Uit 
bovenstaande gegevens blijkt dat het Nederlands bevolkingsonderzoek naar borstkanker 
effectief is in het verlagen van de borstkankersterfte.
Zelfselectiebias
Een probleem van het patiëntcontroleonderzoek is dat zelfselectiebias mogelijk 
een rol speelt in de schatting van het effect. Om hiervoor te corrigeren hebben we 
correctiefactoren berekend met behulp van de incidence-based mortality methode. 
Hierbij wordt een correctiefactor bepaald uit een groep van niet-gescreende en een 
groep van niet-uitgenodigde vrouwen. Beide groepen hebben we geselecteerd uit de 
implementatieperiode van het bevolkingsonderzoek, waarin een deel van de vrouwen 
nog geen uitnodiging had ontvangen.
Voor vijf screeningregio’s in Nederland hebben we correctiefactoren berekend, die 
onderling van elkaar bleken te verschillen. Dit toont aan dat het noodzakelijk is om per 
land of regio een correctiefactor voor zelfselectie te bepalen. In drie regio’s leidt correctie 
voor zelfselectie niet tot een verandering van de OR en in de andere twee regio’s wordt 
het effect van screening groter, dat wil zeggen een iets grotere sterftereductie. Gelet op 
alle regionale correctiefactoren is de invloed van zelfselectie in Nederland echter gering.
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Verschillen in de methode van het patiëntcontroleonderzoek
Recent uitgevoerde patiëntcontroleonderzoeken naar de effectiviteit van het 
bevolkingsonderzoek naar borstkanker tonen verschillen in de grootte van de 
sterftedaling. We hebben gekeken of variaties in de gebruikte studiemethode deze 
verschillen kunnen verklaren. In deze studie hebben we zes patiëntcontroleonderzoeken 
meegenomen, uitgevoerd in East Anglia (Verenigd Koninkrijk), Wales, IJsland, Centraal- en 
Noord-Italië, Zuid-Australië en Zuidoost-Nederland.
De daling in borstkankersterfte in de verschillende patiëntcontroleonderzoeken 
varieerde van 38% tot 70% in de gescreende versus de niet-gescreende groep. Er waren 
veel kleine verschillen in de opzet van de zes patiëntcontroleonderzoeken, maar de 
toegepaste methode was in grote lijnen gelijk. Een deel van het verschil in de grootte van 
de sterftedalingen wordt mogelijk verklaard door het meenemen van gegevens van de 
eerste jaren na de start van het bevolkingsonderzoek en de gebruikte correctiefactoren 
voor zelfselectiebias. Het merendeel van de verschillen zal echter komen door andere 
factoren, zoals de organisatie van het bevolkingsonderzoek.
Effectbepaling van screening en 
het patiëntcontroleonderzoek: een prachtig paar
In dit proefschrift hebben wij aangetoond dat screening, dat wil zeggen de combinatie 
van vroege ontdekking en therapie, leidt tot een substantiële daling in borstkankersterfte 
voor gescreende vrouwen versus niet-gescreende vrouwen (OR = 0.42, 95% CI 0.33-0.53). 
Conclusie: het bevolkingsonderzoek naar borstkanker in Nederland werkt. Verder hebben 
wij laten zien dat het patiëntcontroleonderzoek een betrouwbare en uitvoerbare  methode 
is om het verband tussen screening en borstkankersterfte te monitoren. Hiervoor is het 
essentieel om de OR te corrigeren voor zelfselectiebias, indien het aanwezig is. De invloed 
van zelfselectiebias in Nederland is gering.
Bij toekomstige veranderingen die van invloed kunnen zijn op borstkankersterfte, 
bijvoorbeeld de toename van de incidentie van borstkanker en verbeteringen in de 
therapie, is het patiëntcontroleonderzoek een goed evaluatiemiddel. Bij alle toekomstige 
patiëntcontroleonderzoeken moet rekening gehouden worden met zelfselectie. 
Mogelijk moeten in de toekomst de correctiefactoren voor zelfselectie opnieuw worden 
bepaald. Het zou kunnen dat de correctiefactoren uit de jaren ’90 tot en met ’95 in de 
toekomst niet meer bruikbaar zijn, door bijvoorbeeld veranderingen in deelname aan het 
bevolkingsonderzoek en de redenen hiervan. 
Kortom: de evaluatie van het effect van screening op de borstkankersterfte in 
Nederland en het patiëntcontroleonderzoek zijn een prachtig paar, nu en in de toekomst.
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